Progression from Mild to Pronounced MCI Is Not Associated with Cerebrospinal Fluid Biomarker Deviations
暂无分享,去创建一个
K. Blennow | A. Nordlund | K. Lind | Å. Edman | M. Göthlin | H. Zetterberg | S. Rolstad | C. Eckerström | A. Wallin | K. Blennow | S. Rolstad | A. Nordlund | C. Eckerström | H. Zetterberg | A. Wallin | M. Göthlin | M. Gustavsson | Å. Edman | K. Lind | M. Gustavsson | M. H. Gustavsson
[1] K. Blennow,et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.
[2] Janet B W Williams. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[3] B. Reisberg,et al. Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease , 2008, International Psychogeriatrics.
[4] Magda Tsolaki,et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.
[5] H. Feldman,et al. Apolipoprotein E ε4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging , 2004, Canadian Medical Association Journal.
[6] B. Reisberg,et al. Global Deterioration Scale (GDS). , 1988, Psychopharmacology bulletin.
[7] K. Blennow,et al. Subcortical Vascular Dementia Biomarker Pattern in Mild Cognitive Impairment , 2009, Dementia and Geriatric Cognitive Disorders.
[8] A. Wallin,et al. The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[9] K. Blennow,et al. No association between the α2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression , 2000, Journal of Neural Transmission.
[10] K. Blennow,et al. Stepwise Comparative Status Analysis (STEP): A Tool for Identification of Regional Brain Syndromes in Dementia , 1996, Journal of geriatric psychiatry and neurology.
[11] C. Wikkelsø,et al. Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF , 1996, Journal of neurochemistry.
[12] Kaj Blennow,et al. Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRX.
[13] D. Royall,et al. Bedside Assessment of Executive Cognitive Impairment: The Executive Interview , 1992, Journal of the American Geriatrics Society.
[14] M. Freedman,et al. Frontotemporal lobar degeneration , 1998, Neurology.
[15] K. Blennow,et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.
[16] A. Mitchell,et al. Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia? , 2010, Practical Neurology.
[17] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[18] J. Morris,et al. Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.
[19] H. Chui,et al. Subcortical ischaemic vascular dementia , 2002, The Lancet Neurology.
[20] Simon Lovestone,et al. Is MCI really just early dementia? A systematic review of conversion studies , 2004, International Psychogeriatrics.
[21] M. Sjögren,et al. Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia , 2001, Mechanisms of Ageing and Development.
[22] R. Faber,et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.
[23] K. Blennow,et al. Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds , 2003, Dementia and Geriatric Cognitive Disorders.
[24] K. Blennow,et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.
[25] K. Blennow,et al. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. , 2007, Journal of Alzheimer's disease : JAD.
[26] Wei Zhu,et al. Outcome over seven years of healthy adults with and without subjective cognitive impairment , 2010, Alzheimer's & Dementia.
[27] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.
[28] K. Blennow,et al. Cerebrospinal fluid biomarkers of white matter lesions – cross‐sectional results from the LADIS study , 2010, European journal of neurology.
[29] M. Onofrj,et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.
[30] Georg Kemmler,et al. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine , 2008, Neurobiology of Aging.
[31] G C Roman,et al. Research criteria for subcortical vascular dementia in clinical trials. , 2000, Journal of neural transmission. Supplementum.
[32] P. Scheltens,et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.
[33] H. Gertz,et al. The prognosis of mild cognitive impairment in the elderly. , 1998, Journal of neural transmission. Supplementum.
[34] W. M. van der Flier,et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.